Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma

Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (PDAC) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with PDAC. In this study, we evaluate the anti‐PDAC effects of LY‐1816, a n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Yang, Wei, Meng, Lingwei, Chen, Kai, Tian, Chenyu, Peng, Bing, Zhong, Lei, Zhang, Chunhui, Yang, Xin, Zou, Jun, Yang, Shengyong, Li, Linli
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447837/
https://ncbi.nlm.nih.gov/pubmed/30618127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13929
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars